Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

5.050 -0.130 (-2.51%)
Streaming Delayed Price Updated: 2:20 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annexon, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Analyst Expectations for Annexon's Future ↗
 
Via Benzinga
News headline image
Why Annexon (ANNX) Stock Is Getting Hammered ↗
Annexon Inc (NASDAQ: ANNX) shares are trading lower by some 57.16% to $2.96 Thursday morning. 
Via Benzinga
News headline image
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study ↗
 
Via Benzinga
News headline image
Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET 
From Annexon Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023 ↗
 
Via Benzinga
News headline image
Crude Oil Drops Sharply; Best Buy Earnings Top Expectations ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining more than 200 oints on Thursday. The Dow traded down 0.02% to 32,793.29 while the NASDAQ rose 1.78% to 12,706.89.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results ↗
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 1.5% on Thursday. The Dow traded down 0.20% to 32,733.60 while the NASDAQ rose 1.53% to 12,674.85. The S&P 500,... 
Via Benzinga
News headline image
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR. 
Via Benzinga
News headline image
Why Shares of Annexon Are Plummeting Thursday ↗
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023 ↗
 
Via Benzinga
News headline image
Dow Drops 100 Points; US GDP Tops Estimates ↗
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining over 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.34% to 32,687.15 while the NASDAQ rose 1.36%... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
News headline image
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.